CytomX Therapeutics Inc CTMX
News
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
CytomX Therapeutics to Present at Upcoming November Investor Conferences
CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
CytomX Therapeutics to Present at Upcoming September Investor Conferences
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
